<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11720430</article-id><article-id pub-id-type="pmc">2363949</article-id><article-id pub-id-type="pii">6692120</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2120</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ravaud</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Delaunay</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chevreau</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Coulon</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Debled</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bret-Dibat</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Courbon</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gualde</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bui</surname><given-names>B Nguyen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine, Institut Bergoni&#x000e9;, Regional Cancer Center, Bordeaux, France</aff><aff id="aff2"><label>2</label>UMR 5540 CNRS, Bordeaux, France</aff><aff id="aff3"><label>3</label>Department of Dermato-Oncology, H&#x000f4;pital Saint-Andr&#x000e9;, Bordeaux, France</aff><aff id="aff4"><label>4</label>Department of Medicine, Institut Claudius Regaud, Regional Cancer Center, Toulouse, France</aff><aff id="aff5"><label>5</label>Laboratory of Immunology, Institut Bergoni&#x000e9;, Regional Cancer Center, Bordeaux, France</aff><pub-date pub-type="ppub"><month>11</month><year>2001</year></pub-date><volume>85</volume><issue>10</issue><fpage>1467</fpage><lpage>1471</lpage><history><date date-type="received"><day>07</day><month>02</month><year>2001</year></date><date date-type="rev-recd"><day>26</day><month>07</month><year>2001</year></date><date date-type="accepted"><day>30</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The potential antitumoural effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) led us to evaluate GM-CSF alone or with dacarbazine (DTIC) in metastatic melanoma in first line randomized phase II. Treatment was arm A: GM-CSF: 5&#x02008;&#x003bc;g kg<sup>&#x02212;1</sup>, bid, 14 consecutive days every 21 days and arm B: GM-CSF: 5&#x02008;&#x003bc;g kg<sup>&#x02212;1</sup>, bid, day 2 to day 19 every 21 days and DTIC: 800&#x02008;mg m<sup>&#x02212;2</sup>, day 1 of each cycle. 32 patients (pts) were included, 15 pts in arm A and 17 in arm B. All pts had visceral metastatic sites. 9 had only one metastatic site. The median number of cycles given was 2 in arm A and 3 in arm B. 100&#x00025; and 89.4&#x00025; of the planned dose of GM-CSF was given in arm A and arm B respectively. No objective response was obtained. 19 pts experienced at least WHO grade 3 toxicity. All pts had fever, 29 had a decrease in performance status and 23 had pain. Grade 3 toxicity were fever (38.7&#x00025;), decrease in performance status (32.3&#x00025;), pain (19.4&#x00025;) and dyspnoea (12.5&#x00025;). In this study, GM-CSF alone or in association with DTIC did not induce any antitumoural activity with subsequent toxicity. &#x000a9; 2001 Cancer Research Campaign &#x02002;&#x02002;<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>melanoma</kwd><kwd>GM-CSF</kwd><kwd>DTIC</kwd><kwd>clinical trial</kwd></kwd-group></article-meta></front></article>


